anonymised individual patient data Search Results


anonymised and aggregated data on the management of patients with rheumatoid arthritis  (Lallemand inc)
90
Lallemand inc anonymised and aggregated data on the management of patients with rheumatoid arthritis
Annual average costs for biotherapy acquisition and care for a <t> rheumatoid arthritis </t> patient with adalimumab, etanercept, originator infliximab or biosimilar infliximab: 2012 and 2015 calculated costs (data from the Alsace population 24 )
Anonymised And Aggregated Data On The Management Of Patients With Rheumatoid Arthritis, supplied by Lallemand inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+individual+patient+data/anonymised+and+aggregated+data+on+the+management+of+patients+with+rheumatoid+arthritis/pmc06451627-249-26-6
Average 90 stars, based on 1 article reviews
anonymised and aggregated data on the management of patients with rheumatoid arthritis - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anonymised patient level data  (LEO Pharma)
90
LEO Pharma anonymised patient level data
Annual average costs for biotherapy acquisition and care for a <t> rheumatoid arthritis </t> patient with adalimumab, etanercept, originator infliximab or biosimilar infliximab: 2012 and 2015 calculated costs (data from the Alsace population 24 )
Anonymised Patient Level Data, supplied by LEO Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+individual+patient+data/anonymised+patient+level+data/pmc10116386__jamadermatol___e230627___s002-1926-10-0
Average 90 stars, based on 1 article reviews
anonymised patient level data - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anonymised patient-level data  (Oncopeptides)
90
Oncopeptides anonymised patient-level data
Annual average costs for biotherapy acquisition and care for a <t> rheumatoid arthritis </t> patient with adalimumab, etanercept, originator infliximab or biosimilar infliximab: 2012 and 2015 calculated costs (data from the Alsace population 24 )
Anonymised Patient Level Data, supplied by Oncopeptides, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+individual+patient+data/anonymised+patient+level+data/10__1016_slash_s2352___3026_ascii40_20_ascii41_30044___2-252-16-2
Average 90 stars, based on 1 article reviews
anonymised patient-level data - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Annual average costs for biotherapy acquisition and care for a rheumatoid arthritis patient with adalimumab, etanercept, originator infliximab or biosimilar infliximab: 2012 and 2015 calculated costs (data from the Alsace population 24 )

Journal: European Journal of Hospital Pharmacy. Science and Practice

Article Title: Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?

doi: 10.1136/ejhpharm-2016-000904

Figure Lengend Snippet: Annual average costs for biotherapy acquisition and care for a rheumatoid arthritis patient with adalimumab, etanercept, originator infliximab or biosimilar infliximab: 2012 and 2015 calculated costs (data from the Alsace population 24 )

Article Snippet: The authors are grateful to Pascal Lallemand, Pascale Willem and Bérangère Pierre for extracting the 2012 anonymised and aggregated data on the management of patients with rheumatoid arthritis, and to Rama Piotto for proofreading and linguistic review of the manuscript.

Techniques:

Estimated annual budget savings attributable to the introduction of biosimilar infliximab for the treatment of adult rheumatoid arthritis patients, according to three different scenarios

Journal: European Journal of Hospital Pharmacy. Science and Practice

Article Title: Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?

doi: 10.1136/ejhpharm-2016-000904

Figure Lengend Snippet: Estimated annual budget savings attributable to the introduction of biosimilar infliximab for the treatment of adult rheumatoid arthritis patients, according to three different scenarios

Article Snippet: The authors are grateful to Pascal Lallemand, Pascale Willem and Bérangère Pierre for extracting the 2012 anonymised and aggregated data on the management of patients with rheumatoid arthritis, and to Rama Piotto for proofreading and linguistic review of the manuscript.

Techniques:

Additional rheumatoid arthritis patients who could be treated for 1 year if the savings were spent on biosimilar infliximab

Journal: European Journal of Hospital Pharmacy. Science and Practice

Article Title: Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?

doi: 10.1136/ejhpharm-2016-000904

Figure Lengend Snippet: Additional rheumatoid arthritis patients who could be treated for 1 year if the savings were spent on biosimilar infliximab

Article Snippet: The authors are grateful to Pascal Lallemand, Pascale Willem and Bérangère Pierre for extracting the 2012 anonymised and aggregated data on the management of patients with rheumatoid arthritis, and to Rama Piotto for proofreading and linguistic review of the manuscript.

Techniques: